MyFinsight
Home
Blog
About
Net proceeds from
notes payable...
$675,000
Net cash provided by
financing activities
$675,000
Net increase
(decrease) in cash
$185,498
(468.31%↑ Y/Y)
Canceled cashflow
$489,502
Accounts payable
$177,865
(89.84%↑ Y/Y)
Non-cash interest
expense
$113,910
Stock-based compensation
$41,490
(-2.48%↓ Y/Y)
Prepaid expenses and
other current assets
-$27,187
(74.95%↑ Y/Y)
Depreciation expense
$26,198
(-31.78%↓ Y/Y)
Accrued expenses
$25,757
(16.26%↑ Y/Y)
Vendor expense settled
in shares
$21,000
(40.00%↑ Y/Y)
Amortization of operating
lease right of use...
$19,402
(-44.41%↓ Y/Y)
Net cash used in
investing activities
-$253,027
(-9.27%↓ Y/Y)
Net cash provided by
(used in) operating...
-$236,475
(-189.51%↓ Y/Y)
Canceled cashflow
$452,809
Purchases of property and
equipment
$253,027
(9.27%↑ Y/Y)
Accounts receivable, net
$293,902
(246.75%↑ Y/Y)
Net loss
-$277,601
(80.11%↑ Y/Y)
Deferred revenue
-$77,941
(-105.47%↓ Y/Y)
Inventory, net
$20,981
(-14.34%↓ Y/Y)
Operating lease
liabilities
-$18,859
(42.15%↑ Y/Y)
Back
Back
Cash Flow
Nuo Therapeutics, Inc. (AURX)
Nuo Therapeutics, Inc. (AURX)
source: myfinsight.com